Antares Insights – March 2020
Investing in the time of Coronavirus

Given the rapidly changing world-wide events related to the coronavirus crisis, we continue to meet each day (albeit via teleconference) to discuss and debate our views on stocks and markets and particularly the impact of the coronavirus.

Our initial response
Less than two short weeks ago we wrote that the coronavirus had caused us to re-think our base case for global and Australian growth. We outlined some of our key concerns and the changes we had made to our portfolios at the time. We identified areas that we believed were of high-risk including companies with weak balance sheets, poor liquidity, dependence on stock turn and re-financing risk. And companies where a critical supply chain could be disrupted.

We introduced new stocks that had fallen materially below our valuations or were not directly adversely impacted by the virus (eg consumer staples) and reduced others that we feel will have a more challenged operating environment given the economic slowdown or that could display some of our concerns about balance sheet strength and liquidity. We also increased portfolio diversity by adding a range of stocks in different sectors with different attributes given we are investing in a period of uncertainty.

In the subsequent period we have continued to adjust our portfolios in light of what has happened with the coronavirus spread and how governments and markets have reacted.

The virus spreads...
What was a crisis has now been proclaimed as a global pandemic by the World Health Organisation. Many countries or parts thereof have declared a state of emergency. At this stage no one knows how long the virus will persist nor its ultimate impact on the broader economy. We continue to monitor the daily coronavirus cases (total and China/non-China) as well as the death rate. All indicators at this stage are pointing in the wrong direction. Cases continue to grow at an increasing rate (ex-China) and the death rate has increased to almost 4%.

If there is a positive in the numbers it is that China (as well as South Korea and Singapore) seem to have stemmed the rapid escalation of new cases, demonstrating that significant and early measures can influence the ultimate impact of the Virus on the population and ultimately the economy.

Chart 1: Daily change in number of reported new coronavirus cases globally

![Chart 1: Daily change in number of reported new coronavirus cases globally](source: Bloomberg; 16 March 2020)
Chart 2: Daily change in number of reported new coronavirus cases China v Rest of the World

![Daily Change in Corona Cases](image)

Source: Bloomberg; 16 March 2020

Chart 3: Death rate from coronavirus (%)

![Corona Death Rate](image)

Source: Bloomberg; 16 March 2020

**Which large cap stocks have fared best?**

The top and bottom 15 relative stock returns (in the ASX 100) for the first two weeks of March are shown in Chart 4.

Consumer Staples, Health Care and Communications Services feature prominently in the top 15 stocks while Financials, Consumer Discretionary and Energy stocks make up the majority of the worst performers.
What have we done?

**Dividend Builder and Australian Equities**

As the coronavirus crisis has spread we have become ever more vigilant about balance sheet strength, good liquidity and debt maturity. Can the company survive without a dilutionary capital raising? As China emerges from the crisis supply chain issues may begin to dissipate.

We continue to look for stocks that have fallen materially below our valuations or were not directly adversely impacted by the virus (eg consumer staples, Telstra). And we are looking to companies where we believe they will have a strong business and market share when economies recover. We remain focused on portfolio diversity given we are investing in a period of uncertainty.
Elite and High Growth
We have skewed the portfolio further towards companies with more defensive cashflows that offer upside to our current target prices. In particular we have considered those that have strong balance sheets that will enable them to weather the volatility. Our view is to select those that should emerge from the crisis in a better relative position or have demonstrated a more robust business model that may command a higher price earnings multiple once the crisis has passed.

Over the period from 1-16 March, stocks that we have exited for our Elite Opportunities strategy include QBE Insurance (QBE), Tabcorp (TAH) and Graincorp (GNC). And for our High Growth strategy we have exited GNC, Incitec Pivot (IPL) and Unibail-Rodamco-Westfield (URW). These have been replaced with Metcash (MTS), AGL and A2 Milk (A2M) in both strategies. Both MTS and A2M are consumer staples and AGL provides power to households without oil exposure.

Ex-20
We are using the market volatility to concentrate the portfolio in generally higher quality stocks whereby their industry structure will likely be enhanced by the current upheavals - such as rivals becoming distressed or failing.

In particular we are focusing on stocks where we believe the market is overly concerned by near term earnings risk, not the improvement in longer term franchise value.

We are also combining this with a cyclical tilt to stocks that should benefit from a recovery in the Chinese economy.

Property
The most substantial change to the portfolio has been selling Sydney Airport (SYD) given the news of the implementation of 14-day isolation for all travellers. We are being patient with the cash from the proceeds.

Refining our Business Continuity Plan
From Monday 16 March 2020 we changed the working arrangements for all of the investment staff at Antares. All investment team members are working remotely from home – separate from each other.

- We have full functionality and visibility of systems as if we were in the office
- We continue to have our daily morning meeting through Zoom meetings
- We have multiple chat systems for instantaneous conversations

The only difference from normal circumstances is the physical dislocation which we believe will minimise the risk of simultaneous infection of the team.

As uncertainty and volatility increase, we continue to analyse, debate and discuss the unfolding news in our daily meetings. We don’t know how long the dislocation will last but we continue to actively manage our portfolios and pursue opportunities that we believe will deliver long term growth for our clients.
Important information

This document is provided by Antares Capital Partners Ltd ABN 85 066 081 114, AFSL 234483 (“ACP”) and its investment management division trading under the name of “Antares Equities”.

This information may constitute general advice. It has been prepared without taking account of individual objectives, financial situation or needs and because of that you should, before acting on the information contained in this document, consider the appropriateness of the advice having regard to your personal objectives, financial situation and needs. ACP recommends that you obtain professional advice and read any relevant available information pertaining to the information contained in this document and obtain professional independent financial advice to determine whether the information contained in this document is suitable for you and your investment needs.

You should obtain a Product Disclosure Statement (PDS) relating to the financial products mentioned in this communication issued by ACP, and consider it before making any decision about whether to acquire or continue to hold those products. A copy of the PDS is available upon request by phoning 1800 671 849 or on our website at antarescapital.com.au.

ACP is a subsidiary of the National Australia Bank Limited group of companies. An investment in any financial product offered by any member company of the National Australia Bank group of companies is not a deposit with or liability of, and is not guaranteed by National Australia Bank Limited or its subsidiaries and is subject to investment risk, including possible delays in repayment and loss of income and capital invested. This document has been prepared in good faith, where applicable, using information from sources believed to be reliable and accurate as at the time of preparation, no representation or warranty (express or implied) is given as to its accuracy, reliability or completeness (which may change without notice).

Any opinions expressed in this document constitutes ACP’s judgement at the time of issue and is subject to change. ACP believe that the information contained in this document is correct and that any estimates, opinions, conclusions or recommendations are reasonably held or made as at the time of compilation. However, no warranty is made as to their accuracy or reliability (which may change without notice) or other information contained in this communication.

Past performance is not a reliable indicator of future performance. Returns are not guaranteed and actual returns may vary from any target returns described in this document. Any projection or forward-looking statement in this document is provided for information purposes only and no representation is made as to the accuracy of such projection or that it will be met.

In some cases the information is provided to us by third parties, while it is believed that the information is accurate and reliable, the accuracy of that information is not guaranteed in any way. None of ACP, any other member or the NAB Group, or the employees or directors of the NAB Group are liable for any loss arising from any person relying on information provided by third parties. This information is directed to and prepared for Australian residents only.

ACP disclaims all responsibility and liability for any loss, claim or damage which any person may have and/or suffer as a result of any persons reliance on any information, predictions, performance data and the like contained within this document, whether the loss or damage is caused by, or as a result of any fault or negligence of ACP, its officers, employees, agents and/or its related bodies corporate. Securities mentioned in this communication may no longer be in ACP portfolios. Bloomberg Finance L.P. and its affiliates (collectively, Bloomberg) do not approve or endorse any information included in this publication and disclaim all liability for any loss or damage of any kind arising out of the use of all or any part of any such information.